Core Insights - The company reported annual revenue of approximately RMB 700 million to 720 million for the period ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% [1] Group 1: Revenue Growth - The continuous revenue growth is primarily attributed to the strong performance of all three product lines in the neurointervention business and the expanding market share in the transcatheter aortic valve replacement (TAVR) market, driven by the successful launch of the high-end TaurusMax 3D adjustable TAVR system [1] - All three product lines in neurointervention recorded robust revenue growth, reflecting strong performance of their core products [1] - The vascular access products saw revenue growth due to the increasing sales of the high-performance DCwire microcatheter, leading to a rapid increase in market share [1] Group 2: Product Performance - The hemorrhagic products benefited from the successful launch of the YonFlow blood flow-directed stent, which drove revenue growth for that product line [1] - Revenue growth in the ischemic product segment was mainly due to increased sales of the Syphonet thrombectomy stent and Tethys AS thrombectomy catheter [1] - Despite a price reduction in balloon dilation catheters following the implementation of volume-based procurement in the second half of 2025, sales volume significantly increased, particularly for the Fastunnel delivery balloon dilation catheter, keeping overall revenue stable compared to 2024 [1] Group 3: TAVR Market Expansion - The commercialized TAVR product portfolio was adopted in approximately 130 new hospitals during the reporting period, covering over 780 hospitals as of December 31, 2025 [2] - A total of approximately 3,900 units were implanted during the reporting period, representing a year-on-year growth of 14.4%, significantly exceeding the overall market growth rate [2] - With the registration application for the TaurusTrio transcatheter aortic valve system approved by the National Medical Products Administration in December 2025, the company anticipates a full commercialization in the Chinese aortic regurgitation market [2]

Core Insights - The article highlights the significant advancements and market position of Jiangsu Suzhou-based company, Peijia Medical, particularly its subsidiary, Gaki Bio, in the neuro-interventional medical device sector [1][2][3] Group 1: Company Overview - Gaki Bio, established in 2006, has developed China's first commercialized spring coil and offers a comprehensive range of products addressing hemorrhagic, ischemic, and access solutions [1] - The company is expected to break even in 2024, marking an 18-year journey from obscurity to industry leadership [1] Group 2: Product Development and Market Strategy - The Syphonet thrombectomy stent, launched in February 2022, quickly became the market leader among domestic products, showcasing Gaki Bio's effective research and development strategy [2] - Gaki Bio's approach involves launching a complete suite of products simultaneously to address all surgical needs, enhancing the usability and effectiveness of their devices [2] - The Fastunnel delivery balloon catheter, approved in May 2022, features an integrated design that simplifies complex procedures, reducing the number of steps required in surgeries [3][4] Group 3: Innovation and Clinical Needs - Gaki Bio has developed 16 products that have received approval for sale, with plans to submit 5 to 6 additional registration applications this year, focusing on unmet clinical needs [4] - The company has adopted a "medical-engineering collaboration" innovation methodology, which has proven effective in the neuro-interventional device market [3][4] Group 4: Operational Efficiency and Supply Chain - Gaki Bio has achieved over 90% localization in its supply chain, sourcing more than 90% of its raw materials from domestic suppliers, which enhances cost efficiency and responsiveness [5][6] - The company has implemented lean production standards, resulting in increased operational efficiency and a reported gain of over 20 million yuan in product development [5][6]